Nalbuphine for chronic cough

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jun 2026: Trial started, NCT07671924
  2. 26 Jun 2026: Trial registered, NCT07671924

The trials

NCT07671924: The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

State
Under way
Phase
Phase 2
People
100 planned
Started
22 Jun 2026
Primary completion
Sep 2027
Arms
NAL ER 54 mg BID, NAL ER 27 mg BID, NAL ER 27 mg QD
Results
None posted
  1. 22 Jun 2026: Trial started
  2. 26 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Intapan, Nal er.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.